Centaurus Financial’s Nektar Therapeutics NKTR Stock Holding History

Centaurus Financial’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2	Closed	-$1K	–	1508
2018 Q2	$1K	Buy	+2	New	+$2.31K	﹤0.01%	2112

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Centaurus Financial's NKTR Position: Q3 2018 in Review

Centaurus Financial sold out of Nektar Therapeutics (NKTR) in Q3 2018, closing a stake of 2 shares — an estimated $1K sold.

Centaurus Financial first reported a position in NKTR in Q2 2018 and held it in 1 quarter. The position peaked at $1K in Q2 2018. 388 funds tracked by Wall St. Rank hold NKTR as of Q3 2018.

Centaurus Financial reported no remaining Nektar Therapeutics position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 2 Nektar Therapeutics shares in Q3 2018, an estimated $1K.
Centaurus Financial first reported a position in Nektar Therapeutics in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Nektar Therapeutics position peaked at $1K in Q2 2018.
388 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.